A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care. Issue 12 (December 2022)

• Record Type: Journal Article
• Authors: Taverner, Sofia; Eng, Cindy; Watson, Rebecca; George, Siba; Edwards, Amanda; Williams, David M.; Stephens, Jeffrey W.
• Is Part Of: Diabetes & metabolic syndrome. Volume 16:Issue 12(2022)
• Publication Date: 2022-12
• Subjects: Dapagliflozin -- Empagliflozin -- Canagliflozin -- SGLT2 inhibitor; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2022.102658
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background and aims: Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are associated with diabetic ketoacidosis (DKA), however limited case series are published. Methods: We evaluated the characteristics of patients admitted with SGLT-2i associated DKA. Results: Over 4 months, 22 patients were identified; 45.5% of DKA was not associated with concurrent illness. Conclusion: DKA is not uncommonly associated with SGLT2i with no clear patient factors associated with severity. Highlights: Sodium-glucose co-transporter-2 inhibitor (SGLT-2i) associated DKA was observed in 22 patients over 4-months. No differences in age, diabetes duration, HbA1c or admission biochemistry were seen in those with concurrent illness. Our results observed no clear association between patient characteristics or co-morbidity and SGLT-2i-associated DKA.